View ValuationBonraybio 将来の成長Future 基準チェック /06現在、 Bonraybioの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長30.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.14b (US$98.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (34% accrual ratio). Minor Risk Market cap is less than US$100m (NT$3.14b market cap, or US$98.8m).Reported Earnings • May 19First quarter 2026 earnings released: EPS: NT$0.97 (vs NT$0.97 in 1Q 2025)First quarter 2026 results: EPS: NT$0.97 (down from NT$0.97 in 1Q 2025). Revenue: NT$84.4m (up 19% from 1Q 2025). Net income: NT$23.9m (flat on 1Q 2025). Profit margin: 28% (down from 34% in 1Q 2025). The decrease in margin was driven by higher expenses.Reported Earnings • Mar 11Full year 2025 earnings released: EPS: NT$4.13 (vs NT$3.00 in FY 2024)Full year 2025 results: EPS: NT$4.13 (up from NT$3.00 in FY 2024). Revenue: NT$306.3m (up 37% from FY 2024). Net income: NT$102.5m (up 50% from FY 2024). Profit margin: 34% (up from 31% in FY 2024). The increase in margin was driven by higher revenue.Declared Dividend • Mar 06Dividend of NT$1.50 announcedShareholders will receive a dividend of NT$1.50. Ex-date: 19th March 2026 Payment date: 10th April 2026 Dividend yield will be 0.9%, which is lower than the industry average of 2.6%. Payout Ratios Payout ratio: 33%. Cash payout ratio: 52%.お知らせ • Mar 05+ 1 more updateBonraybio Co., Ltd. announces Annual dividend, payable on April 10, 2026Bonraybio Co., Ltd. announced Annual dividend of TWD 1.5000 per share payable on April 10, 2026, ex-date on March 19, 2026 and record date on March 21, 2026.Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: NT$1.04 (vs NT$0.62 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.04 (up from NT$0.62 in 3Q 2024). Revenue: NT$73.3m (up 28% from 3Q 2024). Net income: NT$25.8m (up 84% from 3Q 2024). Profit margin: 35% (up from 25% in 3Q 2024). The increase in margin was driven by higher revenue.お知らせ • May 03Bonraybio Co., Ltd. to Report Q1, 2025 Results on May 12, 2025Bonraybio Co., Ltd. announced that they will report Q1, 2025 results on May 12, 2025お知らせ • Feb 26+ 1 more updateBonraybio Co., Ltd. Announces Cash Dividend, Payable on April 17, 2025Bonraybio Co., Ltd. announced Cash dividends of TWD 32,348,850 (TWD 1.5 per share). Ex-rights (ex-dividend) trading date is March 27, 2025. Ex-rights (ex-dividend) record date is April 2, 2025. Payment date of common stock cash dividend distribution is April 17, 2025.お知らせ • Feb 15Bonraybio Co., Ltd. to Report Fiscal Year 2024 Results on Feb 24, 2025Bonraybio Co., Ltd. announced that they will report fiscal year 2024 results on Feb 24, 2025New Risk • Apr 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.4% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.70b market cap, or US$83.1m).お知らせ • Mar 22Bonraybio Co., Ltd., Annual General Meeting, Jun 24, 2024Bonraybio Co., Ltd., Annual General Meeting, Jun 24, 2024.New Risk • Feb 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (NT$1.74b market cap, or US$55.6m). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bonraybio は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TWSE:6955 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202632010284114N/A12/31/202530610366100N/A9/30/2025287966292N/A6/30/2025271846390N/A3/31/2025246784369N/A12/31/2024223686980N/A9/30/2024211555668N/A6/30/2024199504759N/A3/31/2024174374351N/A12/31/2023160261727N/A9/30/2023140181220N/A6/30/2023127111019N/A3/31/20231196-19N/A12/31/20221062412N/A12/31/202156-32-30-25N/A12/31/202027-41-29-23N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6955の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6955の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6955の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6955の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6955の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6955の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/09 23:33終値2026/08/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bonraybio Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.14b (US$98.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (34% accrual ratio). Minor Risk Market cap is less than US$100m (NT$3.14b market cap, or US$98.8m).
Reported Earnings • May 19First quarter 2026 earnings released: EPS: NT$0.97 (vs NT$0.97 in 1Q 2025)First quarter 2026 results: EPS: NT$0.97 (down from NT$0.97 in 1Q 2025). Revenue: NT$84.4m (up 19% from 1Q 2025). Net income: NT$23.9m (flat on 1Q 2025). Profit margin: 28% (down from 34% in 1Q 2025). The decrease in margin was driven by higher expenses.
Reported Earnings • Mar 11Full year 2025 earnings released: EPS: NT$4.13 (vs NT$3.00 in FY 2024)Full year 2025 results: EPS: NT$4.13 (up from NT$3.00 in FY 2024). Revenue: NT$306.3m (up 37% from FY 2024). Net income: NT$102.5m (up 50% from FY 2024). Profit margin: 34% (up from 31% in FY 2024). The increase in margin was driven by higher revenue.
Declared Dividend • Mar 06Dividend of NT$1.50 announcedShareholders will receive a dividend of NT$1.50. Ex-date: 19th March 2026 Payment date: 10th April 2026 Dividend yield will be 0.9%, which is lower than the industry average of 2.6%. Payout Ratios Payout ratio: 33%. Cash payout ratio: 52%.
お知らせ • Mar 05+ 1 more updateBonraybio Co., Ltd. announces Annual dividend, payable on April 10, 2026Bonraybio Co., Ltd. announced Annual dividend of TWD 1.5000 per share payable on April 10, 2026, ex-date on March 19, 2026 and record date on March 21, 2026.
Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: NT$1.04 (vs NT$0.62 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.04 (up from NT$0.62 in 3Q 2024). Revenue: NT$73.3m (up 28% from 3Q 2024). Net income: NT$25.8m (up 84% from 3Q 2024). Profit margin: 35% (up from 25% in 3Q 2024). The increase in margin was driven by higher revenue.
お知らせ • May 03Bonraybio Co., Ltd. to Report Q1, 2025 Results on May 12, 2025Bonraybio Co., Ltd. announced that they will report Q1, 2025 results on May 12, 2025
お知らせ • Feb 26+ 1 more updateBonraybio Co., Ltd. Announces Cash Dividend, Payable on April 17, 2025Bonraybio Co., Ltd. announced Cash dividends of TWD 32,348,850 (TWD 1.5 per share). Ex-rights (ex-dividend) trading date is March 27, 2025. Ex-rights (ex-dividend) record date is April 2, 2025. Payment date of common stock cash dividend distribution is April 17, 2025.
お知らせ • Feb 15Bonraybio Co., Ltd. to Report Fiscal Year 2024 Results on Feb 24, 2025Bonraybio Co., Ltd. announced that they will report fiscal year 2024 results on Feb 24, 2025
New Risk • Apr 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.4% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.70b market cap, or US$83.1m).
お知らせ • Mar 22Bonraybio Co., Ltd., Annual General Meeting, Jun 24, 2024Bonraybio Co., Ltd., Annual General Meeting, Jun 24, 2024.
New Risk • Feb 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (NT$1.74b market cap, or US$55.6m).